MEENAKSHI HEGDE to Immunotherapy
This is a "connection" page, showing publications MEENAKSHI HEGDE has written about Immunotherapy.
Connection Strength
0.992
-
Cellular immunotherapy for pediatric solid tumors. Cytotherapy. 2015 Jan; 17(1):3-17.
Score: 0.305
-
Novel approaches and mechanisms of immunotherapy for glioblastoma. Discov Med. 2014 Mar; 17(93):145-54.
Score: 0.296
-
Immunotherapy for pediatric brain tumors: past and present. Neuro Oncol. 2019 10 09; 21(10):1226-1238.
Score: 0.109
-
TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer. Cancer Res. 2018 01 15; 78(2):489-500.
Score: 0.096
-
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol. 2015 May 20; 33(15):1688-96.
Score: 0.080
-
T cells redirected to interleukin-13Ra2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Ra1. Cytotherapy. 2014 Aug; 16(8):1121-31.
Score: 0.075
-
Human epidermal growth factor receptor 2 expression in head and neck squamous cell carcinoma: Variation within and across primary tumor sites, and implications for antigen-specific immunotherapy. Head Neck. 2021 07; 43(7):1983-1994.
Score: 0.030